Non-Small Cell Lung Cancer (NSCLC) Market research report by Delvens focuses on primary sections such as – market segments, market outlook, competitive landscape, and company profiles. The segments provide details in terms of various perspectives such as end-use industry, product or service type, and any other relevant segmentation as per the market’s current scenario which includes various aspects to perform further marketing activity.
The global Non-Small Cell Lung Cancer (NSCLC) market size was estimated at USD 15.1 billion in 2023 and is projected to reach USD 28.3 billion in 2030 at a CAGR of 9.40% during the forecast period 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/non-small-cell-lung-cancer-nsclc-market
The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak. Non-small cell lung cancer accounts for 80-85% of all lung cancer cases worldwide, and this significant share of non-small cell lung cancer has led most of the major market leaders to focus on continuous innovation and increasing the effectiveness of advanced medicines and existing treatment methods.
This is also due to the position of lung cancer as one of the most common cancers in the world and its impact on a significant number of deaths worldwide. Increasing diagnosis of non-small cell lung cancer and increased awareness of developed and developing markets in developed countries are also fueling the growth of the non-small cell lung cancer therapeutics market. This along with increasing R&D investments by key players and inclusion of non-small cell cancer drugs among key market players is also fueling market growth globally. These factors have led to the expansion of the market and increased demand for Non-Small Cell Lung Cancer (NSCLC) solutions.
North America to Dominate the Non-Small Cell Lung Cancer (NSCLC) Market:
· North America is estimated to account for the largest market share during the forecast period. In North America, owing to well-established healthcare infrastructure, higher awareness among people regarding early diagnosis of cancer, presence of favorable reimbursement policies.
· Moreover, the strong presence of key players in this region is expected to boost the North American market growth.
The prominent players in the Non-Small Cell Lung Cancer (NSCLC) market are
· Agennix AG
· Astellas Pharma Inc.
· AstraZeneca
· Bayer AG
· Boehringer Ingelheim
· Bristol-Myers Squibb Company
· Celgene Corporation
· Clovis Oncology
· Eli Lilly and Company
· F. Hoffmann-La Roche Ltd.
· Genentech Inc.
· GlaxoSmithKline plc.
· GSK plc
· Johnson & Johnson Private Limited
· Lupin
· Merck & Co., Inc.
· Millennium Pharmaceuticals, Inc. (Takeda)
· Mylan N.V.
· Novartis AG
· Pfizer Inc. and More
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/non-small-cell-lung-cancer-nsclc-market
Key Findings
· The type segment is further fragmented into Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma and Others. The adenocarcinoma segment is expected to account for a larger market size during the forecast period due to the number of patients with adenocarcinoma and the wide range of drugs used for this indication. The squamous cell carcinoma segment is expected to register a higher CAGR during the forecast period. For example, according to the American Gastroenterological Association, there were approximately 604,100 new cases of esophageal cancer in 2020.
· The treatment segment is further bifurcated into Chemotherapy, Targeted Therapy and Immunotherapy. The targeted therapy is the largest market during the forecast period owing to distinct clinical benefits offered by this therapy such as minimal side effects along with availability of number of targeted therapeutics. In addition, rise in number of people turning to targeted therapy as a form of treatment for cancer, and targeted therapy is successful in upto 80% of cases.
· The distribution channel segment is further bifurcated into Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy. Hospital pharmacy to account for a larger market size during the forecast period. The dominance is due to increase in number of hospitalizations of patients suffering with NSCLC and presence of skilled professionals within these settings.
· The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America, owing to well-established healthcare infrastructure, higher awareness among people regarding early diagnosis of cancer, presence of favorable reimbursement policies and strong presence of key players in this region.
Recent Developments
· In August 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.
· In March 2022, Regeneron and BioNTech expanded their collaboration agreement for the development of Libtayo and FixVac (cemiplimab) Combination to treat advanced NSCLC.
Access Full Report: https://www.delvens.com/report/non-small-cell-lung-cancer-nsclc-market
In addition to the market data for the Non-Small Cell Lung Cancer (NSCLC) Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
Reasons to Acquire
· Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
· Gain authentic and granular data access for the Non-Small Cell Lung Cancer (NSCLC) Market to understand the trends and the factors involved in changing market situations.
· Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
· In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
More Reports from Delvens:
Infusion Therapy Devices Market
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
